



10-04-02

10/07/2002

CASE OP/V-303418/D1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 820012818 US
Express Mail Label Number

October 3, 2002
Date of Deposit

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
KIS ET AL.

Art Unit: 1615

Examiner: Joynes, Robert M

APPLICATION NO: 10/016,361

FILED: DECEMBER 10, 2001

FOR: AUTOCLAVABLE PHARMACEUTICAL COMPOSITIONS
CONTAINING A CHELATING AGENT

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to
copending application No.'s 09/616,151, 09/627,799, 10/033,285, 09/619,349 and 10/134,795.

10/07/2002 KZEW DIE 00000081 190134 10016361

01 FC:126 180.00 CH

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).



Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6946

Date: October 3, 2002

Respectfully submitted,

David E. Wildman
Attorney for Applicants
Reg. No. 40,226

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900



CASE OP/V-30341B/D1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 820012818
Express Mail Label Number

October 3, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

KIS ET AL.

Examiner: Joynes, Robert M

APPLICATION NO: 10/016,361

FILED: DECEMBER 10, 2001

FOR: AUTOCLAVABLE PHARMACEUTICAL COMPOSITIONS
CONTAINING A CHELATING AGENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

David E. Wildman
Attorney for Applicants
Reg. No. 40,226

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6946
Date: October 3, 2002